San Jose, CA (PRWEB) April 27, 2012
Follow us on LinkedIn – Discovered as a simple biological process in the 1990s, RNA interference (RNAi) has come a long way from being used as a research tool in institutions and laboratories, to a leading gene silencing approach in gene function analysis; a technology for drug discovery, drug target validation, high-throughput screening; as well as in the development of a class of new therapeutics, which could interfere with physiological pathways of targeted genes responsible for a particular disease. Over the years, the use of RNAi applications, such as siRNA and miRNA, in industries and academic institutions has witnessed a substantial growth. Having emerged as the most commonly used research tool in functional genomics, RNAi is expected to outshine currently leading biological technologies, such as PCR (Polymerase Chain Reaction).
Presently in the nascent stages, the RNAi industry is gaining ground in terms of therapeutics, with its most promising application being high-throughput screening. RNAi-based therapeutics are expected to emerge as a promising new class of drugs in a number of clinical areas. Given the role played by RNA interference in selective regulation and gene silencing, and the fact that it is a naturally occurring phenomenon in a number of organisms, RNAi-based therapeutics could potentially target a broad range of proteins, compared to a small class of proteins targeted by the existing classes of drugs. Druggable targets for RNAi-based therapeutics could be easily identified using bioinformatics tools, in comparison to the extensive lead optimization techniques required in case of the existing classes of drugs, such as protein therapeutics and small molecules. The ease of identifying drug targets using bioinformatics is expected to drive the growth of RNAi-based therapeutics development. In addition, the increasing use of RNAi technologies in areas, such as agriculture and disease diagnostics, is also expected to further fuel market growth.
The US and Europe together account for a lion’s share of the global RNAi market, as stated by the new market research report on RNA Interference (RNAi). The US, which represents the single largest market for RNA interference, is witnessing a gradual transition owing to the changing focus from low-throughput to high- and medium-throughput research as well as adoption of in-vivo methodologies and applications. As such, the market presents several prospects in the form of RNAi-based applications, particularly those that facilitate highly specific inhibition of gene expression. Europe constitutes the second largest as well as fastest growing market, growing at a compounded annual rate of 13.6% over the analysis period. Application-wise, RNAi in drug discovery and target validation, and RNAi reagents together dominate the RNAi market. However, in the coming years, RNAi reagent is expected to constitute the largest area of RNAi application. siRNA synthesis is expected to emerge as the fastest growing application area, with a CAGR of more than 15.8% over the analysis period.
Of the several players presently operating in the RNAi market, few started initially by addressing the need for kits and reagents required for research in institutions, and other industrial and government organizations. Thereafter, the market witnessed an increased interest in the RNAi-based therapeutics field, with several players, including major pharmaceutical and biotech companies, pursuing drug discovery, basic research, therapeutic applications and development programs, as well as exploring the potential of this natural process in the treatment of various diseases. With an expected change in patent and license scenario in the pharmaceutical industry, it is likely that more companies would explore RNAi technology to provide RNAi-based products. A major part of investment activity is centered on siRNA optimization, development of siRNA alternatives, as well as improving its presence in the RNAi delivery technologies, such as lipid-based and nanoparticle-based delivery platforms. And though Nanoparticle RNAi delivery is the most important segment, the Nucleic Acid and Aptamer-based deliveries are expected to exhibit significant growth prospects in the ensuing years.
Major players profiled in the report include Alnylam Pharmaceuticals Inc., Benitec Limited, Bioneer Corp., Calando Pharmaceuticals Inc., Cenix BioScience GmbH, Devgen NV, Dharmacon Inc., Dicerna Pharmaceuticals Inc., Genesis Research & Development Corporation Limited, OPKO Health Inc., Polyplus-transfection SA, Quark Pharmaceuticals Inc., among others.
The research report titled “RNA Interference (RNAi): A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the RNA Interference, its applications, industry overview, industry outlook, regulatory approvals, technological innovations, recent industry activity, and profiles of major/niche global market participants. The report provides annual value sales estimates and projections for RNA Interference market for the years 2009 through 2017 for the following application areas - Drug Discovery and Target Validation, Reagents, and siRNA synthesis. Also, a seven-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/